Johnson & Johnson (JNJ) Cash from Investing Activities Growth (5y) (2014 - 2026)

Johnson & Johnson (JNJ) Cash from Investing Activities Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn -

Historic Data

Download Data
DateValue
Mar 29, 2026 -41.24%
Dec 28, 2025 10.71%
Sep 28, 2025 35.40%
Jun 29, 2025 -19.41%
Mar 30, 2025 12.56%
Dec 29, 2024 0.36%
Sep 29, 2024 -13.72%
Jun 30, 2024 -50.24%
Mar 31, 2024 20.01%
Dec 31, 2023 -20.49%
Oct 1, 2023 21.01%
Jul 2, 2023 -79.79%
Apr 2, 2023 41.05%
Jan 1, 2023 -78.10%
Apr 3, 2022 -31.17%
Apr 4, 2021 34.52%
Sep 27, 2020 -36.93%
Jun 28, 2020 -16.18%
Mar 29, 2020 20.14%
Dec 29, 2019 14.39%